Aziz Nazha, MD, discusses a new mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).
Aziz Nazha, MD, hematologist, medical oncologist, Cleveland Clinic, Taussig Cancer Institute, discusses a new mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS), which was presented at the Society of Hematologic Oncology (SOHO) 2015 Annual Meeting.
Nazha and his colleagues treated 122 patients with MDS and myeloid malignancies between 2000 and 2012. Patients were given azacitidine or decitabine for at least four cycles. Using a panel of 62 gene mutations, Nazha and his team looked at patients and divided them between responders and nonresponders; responders being those who achieved complete remission, partial remission, or hematologic improvements.
By looking at the mutation distribution between each group, it was found that mutations, such as IDH1 and IDH2, had higher prevalence among responders, says Nazha. ASXL1 mutations were more prevalent in nonresponders.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More